Antibody therapy in neurodegenerative disease

Reviews in the Neurosciences

Volumn 21, Issue 4, 2010, Pages 273-287

  Southwell, Amber L ^a   Patterson, Paul H ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alzheimer's disease; Huntington's disease; Immunization; Immunotherapy; Intrabody; Parkinson's disease; Vaccination

Indexed keywords

ALPHA SYNUCLEIN; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIBODY; BAPINEUZUMAB; EPITOPE; HUNTINGTIN; IMMUNOGLOBULIN; LY 2062430; MYELIN BASIC PROTEIN; TAU PROTEIN;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE SEVERITY; GLIOSIS; HUMAN; HUNTINGTON CHOREA; IMMUNIZATION; IMMUNOTHERAPY; LEWY BODY; MENINGOENCEPHALITIS; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROCESSING; REVIEW;

EID: 78349301194     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2010.21.4.273     Document Type: Review

References (82)

1. Aguzzi A, Rajendran L. The cytosolic spread of amyloids, prions and prionoids. Neuron 2009;64: 783-90.
2. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004;431:805-810. (Pubitemid 39434070)
3. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27:9115-29. (Pubitemid 47312068)
4. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet 2007; 16:2600-15. (Pubitemid 47617727)
5. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Rev Neurosci 2007; 8:663.
6. Benner EJ, Mosely RL, Destache CJ, Lewis TB, Jackson-Lewis V, Gorantla S, Nemachek C, Green SR, Przedborski S, Gendelman HE. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004; 101:9035-40.
7. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JAR. Consequence of Aβ immunization on the vasculature of human Alzheimers disease brain. Brain 2008; 131:3299-10.
8. Chen S, Berthelier V, Hamilton JB, O'Nuallai B, Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 2002; 41:7391-9.
9. Colby DW, Garg P, Holden T, Chao G, Webster JM, Messer A, Ingram VM, Wittrup KD. Development of a human light chain variable domain (VL) Intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J Mol Bio 2004; 342:901-12.
10. Colby DW, Chu Y, Cassady JP, Duennwald M, Zazulak H, Webster JM, Messer A, Lindquist S, Ingram VM, Wittrup KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci USA 2004; 101: 7616-21.
11. Danny MH. Protein misfolding inside cells: The case of huntingtin and Huntington's disease. IUBMB Life 2008; 60:724-8.
12. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
13. Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS. Alpha synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 2005; 170:47-59.
14. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002; 52:253-6.
15. Eliezer D, Kutuay E, Bussell R, Browne G. Conformational properties of α-synuclein in its free and lipid-associated states. J Mol Biol 2001;307:1061-73.
16. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007;368:1132-44.
17. Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem 2009;284:11048-58.
18. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 1998;7:1463-74.
19. Fillit H, Hess G, Hill J, Bonner P, Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurol 2009;73:180-5.
20. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M; AN1792(QS-21)-201 Study. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurol 2005; 64:1563-72.
21. Fukuchi K-i, Tahara K, Kim H-D, Maxwell JA, Lewis TL, Accavitti-Loper MA, Kim H, Ponnazhagan S, Lalonde R. Anti-Aβ single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006; 23:502-11.
22. Glabe CG, Kayed R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurol 2006; 66:S74-8.
23. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010 ; 140:918-34.
24. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009; 64:828-40.
25. Hare JF. Intracellular pathways of folded and misfolded amyloid precursor protein degradation. Arch Biochem and Biophys 2006; 451:79-90.
26. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38:547-54.
27. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones AB, Bullock B, Love S, Neal JW, Zotova E, Nicoll JAR. Long-term effects of Aβ1-42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase I trial. Lancet 2008; 372:216-23.
28. The Huntington's disease collaborative research group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83.
29. Imarisio S, Carmichael J, Korolchuk V, Chen C-W, Saiki S, Rose C, Krishna G, Davies JE, Ttofi E, Underwood BR, Rubinsztein DC. Huntington's disease: from pathology and genetics to potential therapies. J Biochem 2008; 412:191-209. (Pubitemid 351758226)
30. Jackson GR, Sang T, Khoshnan A, Ko J, Patterson PH. Inhibition of mutant huntingtin-induced neurodegeneration In vivo by expression of a polyproline-binding single chain antibody. SFN abstract 2004; 938.5.
31. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-9. (Pubitemid 36444329)
32. Kayed R and Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol 2009;21:359-63.
33. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA 2002; 99:1002-7. (Pubitemid 34106625)
34. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IκB kinase complex and nuclear factor-κB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24:7999-8008. (Pubitemid 39280819)
35. Ko J, Ou S, Patterson PH. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res Bull 2001;56:319-29. (Pubitemid 33062356)
36. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggre-gation and cytotoxicity. PLoS One 2009;4:e5727.
37. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95: 6448-53. (Pubitemid 28249033)
38. Lansbury PT Jr. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 1999; 96:3342-4.
39. Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001;8:4764-4769. (Pubitemid 32295050)
40. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nature Rev Neurol 2010; 6:108-19.
41. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE. Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid β, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 2006; 26:11923-8. (Pubitemid 44772103)
42. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clinical Inv 2006; 116:193-201. (Pubitemid 43121804)
43. Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C, Lyubchenko Y, Goud G, Sierks MR. Single chain variable fragments against β-Amyloid (Aβ) can inhibit Aβ aggregation and prevent Aβ-induced neurotoxicity. Biochemistry 2004; 43: 6959-67. (Pubitemid 38720514)
44. Lo ASY, Zhu Q, Marasco WA. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol 2008; 181:343-73.
45. Lynch SM, Zhou C, Messer A. An scFv intrabody against the non amyloid component of α-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 2008; 377:136-47.
46. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005;46: 857-68. (Pubitemid 40805347)
47. Miller TW, Shirley TL, Wolfgang WJ, Kang X, Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 2003; 7:572-9. (Pubitemid 36626236)
48. Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol Dis 2005;19:47-56. (Pubitemid 40552820)
49. Murphy RC, Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Mol Brain Res 2004;121:141-5. (Pubitemid 38224179)
50. Nakamura KK, Aminoff MJMJ. Huntington's disease: clinical characteristics, pathogenesis and therapies. Drugs Today 2007; 4397-116.
51. Nannenga BL, Zameer A, Sierks MR. Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and α-synuclein aggregates. FEBS Letters 2008; 582:517-522.
52. Oddo S, Billings L, Kessiak JP, Cribbs DH, LaFerla FM. Immunotherapy leads to early, but not late, hyperphosphorylated tau aggregates via the proteosome. Neuron 2004;43:321-32. (Pubitemid 39061125)
53. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. β-site specific intrabodies to decrease and prevent generation of Alzheimer's Aβ peptide. J Cell Biol 2005; 168:863-8. (Pubitemid 40397001)
54. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xironerisiou G, Papadimitriou A, Kafofoutis A, Buchman VL. Autoantibodies to alpha-synuclein in inherited Parkinson's disease. J Neurochem 2007; 101:749-56.
55. Passani LA, Bedford MT, Faber PW, McGinnis KM, Sharp AH, Gusella JF, Vonsattel J-P, MacDonald ME. Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. Hum Mol Genet 2000;9:2175-2182.
56. Peters MF, Nucifora FC, Kushi J, Seaman HC, Cooper JK, Herring WJ, Dawson VL, Dawson TM, Ross CA. Nuclear targeting of mutant huntingtin increases toxicity. Mol Cell Neurosci 1999;14:121-128. (Pubitemid 29444882)
57. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004;25: 1605-12.
58. Qin Z-H, Wang Y, Sapp E, Cuiffo B, Wanker E, Hayden MR, Kegel KB, Aronin N, DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J Neurosci 2004; 24:269-81. (Pubitemid 38181691)
59. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 2003;42:14328-34. (Pubitemid 37499430)
60. Relkin NR, Szabo P, Adamiak B, Burgut, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R Weksler ME. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36.
61. Reynolds AD, Stone DK, Hutter JAL, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate neurodegeneration in a model of Parkinson's disease. J Immunol 2010; 184:2261-71.
62. Rockabrand E, Slepko N, Pantalone A, Nukala VN, Kazantsev A, Marsh JL, Sullivan PG, Steffan JS, Sensi SL, Thompson LM. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 2007;16:61-77. (Pubitemid 46156597)
63. Rosenmann H, Grigoriadis N, Kamssis D, Boimel M, Touloumi O, Ovadia H, Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006;63:1459-67. (Pubitemid 44547559)
64. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurol 2009;73:2061-70.
65. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyoid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7. (Pubitemid 29327547)
66. Schwartz M, Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease. Molec Pyschiat 2010; 15:342-54.
67. Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc Natl Acad Sci USA 2005; 102:11402-7. (Pubitemid 41153832)
68. Small SA, Duff K. Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008; 60:534-42.
69. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro firbrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452-5. (Pubitemid 26038175)
70. Solomon B, Koppel R, Frenkel D, Hanan-Aharon E. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94: 4109-12. (Pubitemid 27180507)
71. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 2008;28:9013-20.
72. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009;29:13589-602.
73. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu Y-Z, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000;97:6763-8. (Pubitemid 30412788)
74. Sudol KL, Mastrangelo MA, Narrow WC, Frazer ME, Levites YR, Golde TE, Federoff HJ, Bowers WJ. Generating differentially targeted amyloid-□ specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol Ther 2009; 17:2031-40.
75. Teitelbaum D, Aharoni R, Sela M, Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA. 1991;88: 9528-32. (Pubitemid 21915664)
76. Thakur AK, Jayaraman M, Mishra R, Thakur M, Chellgren VM, L Byeon I-J, Anjum DH, Kodali R, Creamer TP, Conway JF, M Gronenborn A, Wetzel R. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat Struct Mol Biol 2009; 16:380-9.
77. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu Y-Z, Lau AL, Massey A, Hayden MR, Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS. IKK phosphorylates huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009;187:1083-99.
78. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009; 6: 144-51.
79. Wang C-E, Zhou H, McGuire JR, Cerullo V, Lee B, Li S-H, Li X-J. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol 2008; 181:803-16. (Pubitemid 351786985)
80. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005;102:11563-8. (Pubitemid 41153859)
81. Yuan B, Sierks MR. Intracellular targeting and clearance of oligomeric □-synuclein alleviates toxicity in mammalian cells. Neurosci Lett 2009; 459:16-18.
82. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004; 10:1023-31. (Pubitemid 39625246)